303 related articles for article (PubMed ID: 35288695)
1. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
Smith M; Dai A; Ghilardi G; Amelsberg KV; Devlin SM; Pajarillo R; Slingerland JB; Beghi S; Herrera PS; Giardina P; Clurman A; Dwomoh E; Armijo G; Gomes ALC; Littmann ER; Schluter J; Fontana E; Taur Y; Park JH; Palomba ML; Halton E; Ruiz J; Jain T; Pennisi M; Afuye AO; Perales MA; Freyer CW; Garfall A; Gier S; Nasta S; Landsburg D; Gerson J; Svoboda J; Cross J; Chong EA; Giralt S; Gill SI; Riviere I; Porter DL; Schuster SJ; Sadelain M; Frey N; Brentjens RJ; June CH; Pamer EG; Peled JU; Facciabene A; van den Brink MRM; Ruella M
Nat Med; 2022 Apr; 28(4):713-723. PubMed ID: 35288695
[TBL] [Abstract][Full Text] [Related]
2. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
3. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
4. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
6. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.
Stein-Thoeringer CK; Saini NY; Zamir E; Blumenberg V; Schubert ML; Mor U; Fante MA; Schmidt S; Hayase E; Hayase T; Rohrbach R; Chang CC; McDaniel L; Flores I; Gaiser R; Edinger M; Wolff D; Heidenreich M; Strati P; Nair R; Chihara D; Fayad LE; Ahmed S; Iyer SP; Steiner RE; Jain P; Nastoupil LJ; Westin J; Arora R; Wang ML; Turner J; Menges M; Hidalgo-Vargas M; Reid K; Dreger P; Schmitt A; Müller-Tidow C; Locke FL; Davila ML; Champlin RE; Flowers CR; Shpall EJ; Poeck H; Neelapu SS; Schmitt M; Subklewe M; Jain MD; Jenq RR; Elinav E
Nat Med; 2023 Apr; 29(4):906-916. PubMed ID: 36914893
[TBL] [Abstract][Full Text] [Related]
7. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
8. The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy.
Schubert ML; Rohrbach R; Schmitt M; Stein-Thoeringer CK
Front Immunol; 2021; 12():670286. PubMed ID: 34135898
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
11. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.
Shahid S; Ramaswamy K; Flynn J; Mauguen A; Perica K; Park JH; Forlenza CJ; Shukla NN; Steinherz PG; Margossian SP; Boelens JJ; Kernan NA; Curran KJ
Transplant Cell Ther; 2022 Feb; 28(2):72.e1-72.e8. PubMed ID: 34852305
[TBL] [Abstract][Full Text] [Related]
12. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Li P; Liu Y; Liang Y; Bo J; Gao S; Hu Y; Hu Y; Huang H; Huang X; Jing H; Ke X; Li J; Li Y; Liu Q; Lu P; Mei H; Niu T; Song Y; Song Y; Su L; Tu S; Wang J; Wu D; Wang Z; Xu K; Ying Z; Yang Q; Zhang Y; Shi F; Zhang B; Zhang H; Zhang X; Zhao M; Zhao W; Zhao X; Huang L; Zhu J; Qian W; Han W; Liang A
Cancer Biol Med; 2023 Mar; 20(2):129-46. PubMed ID: 36861439
[TBL] [Abstract][Full Text] [Related]
13. Post-infusion CAR T
Good Z; Spiegel JY; Sahaf B; Malipatlolla MB; Ehlinger ZJ; Kurra S; Desai MH; Reynolds WD; Wong Lin A; Vandris P; Wu F; Prabhu S; Hamilton MP; Tamaresis JS; Hanson PJ; Patel S; Feldman SA; Frank MJ; Baird JH; Muffly L; Claire GK; Craig J; Kong KA; Wagh D; Coller J; Bendall SC; Tibshirani RJ; Plevritis SK; Miklos DB; Mackall CL
Nat Med; 2022 Sep; 28(9):1860-1871. PubMed ID: 36097223
[TBL] [Abstract][Full Text] [Related]
14. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
Shalabi H; Qin H; Su A; Yates B; Wolters PL; Steinberg SM; Ligon JA; Silbert S; DéDé K; Benzaoui M; Goldberg S; Achar S; Schneider D; Shahani SA; Little L; Foley T; Molina JC; Panch S; Mackall CL; Lee DW; Chien CD; Pouzolles M; Ahlman M; Yuan CM; Wang HW; Wang Y; Inglefield J; Toledo-Tamula MA; Martin S; Highfill SL; Altan-Bonnet G; Stroncek D; Fry TJ; Taylor N; Shah NN
Blood; 2022 Aug; 140(5):451-463. PubMed ID: 35605184
[TBL] [Abstract][Full Text] [Related]
15. Toxicities of CD19 CAR-T cell immunotherapy.
Hirayama AV; Turtle CJ
Am J Hematol; 2019 May; 94(S1):S42-S49. PubMed ID: 30784102
[TBL] [Abstract][Full Text] [Related]
16. Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy.
Rubin DB; Al Jarrah A; Li K; LaRose S; Monk AD; Ali AB; Spendley LN; Nikiforow S; Jacobson C; Vaitkevicius H
JAMA Neurol; 2020 Dec; 77(12):1536-1542. PubMed ID: 32777012
[TBL] [Abstract][Full Text] [Related]
17. Severe persistent neurotoxicity associated with CAR T therapy in children.
Andrew EC; Hughes D; Gilsenan M; Mignone C; Khaw SL; Wang SS
Br J Haematol; 2023 Nov; 203(4):651-655. PubMed ID: 37528536
[TBL] [Abstract][Full Text] [Related]
18. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
19. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity.
Jess J; Yates B; Dulau-Florea A; Parker K; Inglefield J; Lichtenstein D; Schischlik F; Ongkeko M; Wang Y; Shahani S; Cullinane A; Smith H; Kane E; Little L; Chen D; Fry TJ; Shalabi H; Wang HW; Satpathy A; Lozier J; Shah NN
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295816
[TBL] [Abstract][Full Text] [Related]
20. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
